Epitalon is sold as a telomere and longevity peptide, and the pages selling it cite decades of human research. The research exists. The difficulty is that most of it was done on a different substance.
This page reports what published sources state, with the dates they were read. It is not a protocol and contains no recommendation.
Two substances, one name
Epithalamin is a peptide preparation extracted from the bovine pineal gland — a biological extract, containing many peptides, prepared from animal tissue. It was developed in Leningrad in the 1970s and studied in people through the 1980s and 1990s.
Epitalon is a synthetic tetrapeptide: four amino acids, Ala-Glu-Asp-Gly, PubChem CID 219042, molecular weight 390.35 g/mol. It was designed afterwards, from the amino acid composition of the extract.
The 2025 review in Int J Mol Sci puts the relationship plainly: epitalon "was synthesized based on the amino acids composition of Epithalamin, a bovine pineal gland extract". That sentence is the whole problem in one line. A synthetic molecule inspired by the composition of a complex extract does not inherit that extract's clinical record — not its effects, not its dose, not its safety profile. Deriving one from the other is a hypothesis, and testing it requires studying the peptide.
What the human studies actually administered
Every human study retrieved for this page used the extract or a comparable product. None used the tetrapeptide on its own with a stated dose.
| Study | What was given | Population | Reported |
|---|---|---|---|
| Dekster et al., Vopr Onkol 1979 | "polypeptide extract of the epiphysis (epithalamin)" | cervical cancer patients, plus mice | improved cell-immunity indices; antitumour action |
| Slepushkin et al., Probl Endokrinol 1983 | epithalamin | 49 people of both sexes, plus rats | gonadotropin and prolactin levels moved toward normal from either direction; unchanged when initially normal |
| Khavinson et al., Neuro Endocrinol Lett 2002 | epitalon | patients with degenerative retinal lesions | "positive clinical effect in 90% of the cases" |
| Labunets et al., Bull Exp Biol Med 2007 | epithalamin, 6 courses | elderly chronic coronary patients, 30 months | immune and endocrine rhythms retained |
| Trofimova et al., Adv Gerontol 2017 | Pineamin, course dose 100 mg | 55 elderly patients | night 6-sulfatoxymelatonin excretion 1.9× pre-treatment |
The 2002 retinal paper is the one entry that names epitalon in people. Its abstract reports a 90 percent response rate with no control group, no participant count, and no dose — from the institute that developed the compound.
The 2017 entry is the only sourced course figure in the table, and it belongs to Pineamin, a third product: another polypeptide complex, with one of the paper's authors affiliated to Geropharm, the company that markets it.
So the honest summary is: there is no published human dose for epitalon. Not a small one, not a disputed one — none that this page could open. The figures circulating in the research market do not trace to a source.
Why the count of papers is misleading
A PubMed search across the three names returned 190 records on 13 September 2026, 57 human-tagged, 5 carrying the randomised-controlled-trial publication type. Quoted alone, that sounds like a reasonable evidence base.
Three things deflate it:
The human-tagged records are mostly about the extract. Searching "epitalon OR epithalon OR epithalamin" pools two substances, and the human work sits overwhelmingly on the epithalamin side.
ClinicalTrials.gov holds nothing. Zero registrations under any of the three names. Every other compound in this catalogue with a comparable reputation has at least an unfinished registration to point at; this one does not.
Concentration of authorship. A large share of the literature comes from one institute in Saint Petersburg, much of it under one author, whose 2002 overview occupies 134 pages of a single journal supplement. Originator groups publishing first is normal. The absence of independent replication after twenty-five years is the part that matters, and the 2025 review notes in passing that even the basic physico-chemical and structural work on the peptide "remains quite limited."
A 2026 advisory vote, and what it rests on
On 23-24 July 2026 FDA's Pharmacy Compounding Advisory Committee reviewed seven nominated peptides for the 503A bulks list. Epitalon was recommended, 7 votes to 5 with one abstention — one of six the committee backed, against emideltide, which it declined.
The vote is advisory; FDA has not acted on it, and it does not make the compound approved, legal for any particular use, or supported by evidence it does not have. It is recorded here because it is the closest thing to a regulatory assessment this compound has received, and because the margin — 7 to 5 with an abstention — was the narrowest of the six that passed. What the committee had available to weigh is what this page has set out: no registered trial, no human dose, and a human literature belonging largely to a different substance. The scope of that vote is covered on our page on cognitive peptides.
The modern paper, read accurately
The most-cited recent result is Al-Dulaimi and colleagues in Biogerontology, September 2025: epitalon produced dose-dependent telomere lengthening in normal human epithelial and fibroblast cells through hTERT and telomerase upregulation, and in breast cancer cell lines through alternative lengthening of telomeres.
Two qualifications travel with it and are usually dropped. It is cell-culture work — cells in a dish, not people, and "dose-dependent" there means a concentration in a culture medium, which does not convert into a milligram figure for a person. And the paper carries a published erratum, issued in Biogerontology in November 2025.
It is a real result about what the molecule does to cells. It is not evidence of an effect in a human being, and it is not a dose.
What is not established
- No human dose of the tetrapeptide, from any source this page could open.
- No registered trial, anywhere, under any of its names.
- No approved product in the US label database, and no labelled route or schedule.
- No independent replication of the originator institute's human findings.
- No adverse-event record. FDA's reporting system holds zero reports naming epitalon — which, as our count of that database sets out, reflects the absence of a reporting channel rather than the absence of risk.
- No human telomere data. The telomere finding is in cultured cells.
What a reader can check in five minutes
Open the 2025 Int J Mol Sci review (PMID 40141333) and read its first sentence about how epitalon was synthesized — the extract-versus-peptide distinction is stated there in the authors' own words. Then search ClinicalTrials.gov for epitalon, epithalon and epithalamin in turn, and confirm all three return nothing.
Then take any retail page selling epitalon and check its citations one at a time against what the study actually administered. The word to look for in the abstract is extract.
Related on this site
- How to read a dosing claim — the checks that separate a sourced figure from a repeated one
- FDA's category 2 list, indexed — where epitalon sits in FDA's compounding records
- DSIP dosage — a compound with the opposite problem: real human trials, and they disagree
- Why the adverse-event record is nearly empty — 85 reports across fourteen compounds, and the reason
Sources and dates
- PubChem CID 219042, epitalon — formula and molecular weight. Read 13 September 2026.
- PubMed record counts via NCBI E-utilities across epitalon, epithalon, epithalamin and AEDG. Run 13 September 2026.
- ClinicalTrials.gov API v2 — queries for epitalon, epithalon and epithalamin. Run 13 September 2026, all returning zero.
- DailyMed SPL database and openFDA adverse event endpoint — queries for epitalon. Run 13 September 2026, both returning zero.
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. PMID 40141333.
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID 40908429. Erratum: Biogerontology. 2025;27(1):1.
- Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365–8. PMID 12195242.
- Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11–144. PMID 12374906.
- Trofimova SV, Linkova NS, Klimenko AA, Kvetnaia TV, Khavinson VK. Pineamin increased pineal melatonin synthesis in elderly people. Adv Gerontol. 2017;30(3):422–6. PMID 28849889.
- Slepushkin VD, et al. Effect of the epiphysial preparation epithalamin on the gonadotropic function of the hypophysis. Probl Endokrinol (Mosk). 1983;29(6):51–4. PMID 6419222.
- Dekster LI, et al. Action of a polypeptide epiphyseal extract on cervical cancer. Vopr Onkol. 1979;25(3):7–9. PMID 373241.
- FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, nominated-but-withdrawn section. Content current as of 22 April 2026; read 13 September 2026.